---
schema_version: "secwatch.filing_event.v1"
accession: "0001826667-25-000115"
form_type: "8-K"
ticker: "TLSI"
cik: "0001826667"
company_name: "TriSalus Life Sciences, Inc."
filed_at: "2025-08-12T23:59:59+00:00"
generated_at: "2026-05-17T14:48:46.986258+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# TriSalus Q2 revenue $11.2M (+52% YoY); reaffirms 50% FY growth; net loss $9.0M

## Summary
- Revenue $11.2M, +52% YoY, +22% sequential; gross margin 84% vs 88%.
- Operating loss improved to $7.3M from $8.2M; net loss $9.0M ($0.27 diluted EPS loss).
- Reaffirmed FY2025 revenue growth at least 50%; cash $26.5M, runway to positive adj. EBITDA H1 2026.
- Launched TriNav FLX for tortuous vessels; early sales exceeded internal projections.
- Simplified capital structure via exchange of Series A Preferred stock completed post-quarter.

## SEC filing metadata
- accession: 0001826667-25-000115
- form_type: 8-K
- ticker: TLSI
- cik: 0001826667
- company_name: TriSalus Life Sciences, Inc.
- filed_at: 2025-08-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1826667/000182666725000115/0001826667-25-000115-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1826667/000182666725000115/tlsi-20250812.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001826667-25-000115
- JSON: https://secwatch.observer/filing/0001826667-25-000115.json
- Plain text: https://secwatch.observer/filing/0001826667-25-000115.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.